GlassScriptPhysician profile
Andrew B Cummins
NPI 1699917096
$8,064.74
in general payments reported to CMS, 2019-2025
37 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,339 · 2020: $254 · 2021: $653 · 2022: $1,019 · 2023: $1,298 · 2024: $1,892 · 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,800.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,781.67 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Janssen Biotech, INC. | $947.94 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $565.63 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $558.67 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $416.76 | 2019-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $345.64 | 2023-2025 | |
| Madrigal Pharmaceuticals | $287.89 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $281.73 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $261.35 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $208.92 | 2019-2024 | Ocaliva |
| Ferring Pharmaceuticals INC. | $138.40 | 2019-2023 | Rebyota |
| Shionogi INC | $127.99 | 2019 | |
| Nestle Healthcare Nutrition INC. | $119.40 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $94.34 | 2025 | Zenpep |
| Braintree Laboratories, INC. | $93.04 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $89.85 | 2024-2025 | Pillcam |
| Lilly USA, LLC | $83.75 | 2024-2025 | Omvoh |
| Celgene Corporation | $77.52 | 2022-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $74.11 | 2019-2024 | |
| Romark Laboratories, Lc | $70.29 | 2019-2020 | |
| Vivus LLC | $57.53 | 2019-2025 | Qsymia, Pancreaze |
| Allergan, INC. | $56.03 | 2019-2020 | |
| Capsovision, INC. | $50.85 | 2023-2024 | Capsocam Plus |
| Celltrion USA INC. | $47.83 | 2024-2025 | Vegzelma |
| Ardelyx, INC. | $45.15 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $38.74 | 2024 | Dificid |
| Digestive Care, INC. | $22.96 | 2020 | |
| Shire North American Group INC | $20.82 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.69 | 2024 | Voquezna |
| Echosens North America, INC. | $17.61 | 2024 | Fibroscan |
| Qol Medical, LLC | $17.47 | 2025 | Sucraid |
| Axonics, INC. | $17.43 | 2021 | |
| Orphalan INC | $16.40 | 2025 | Cuvrior |
| Pentax of America, INC. | $11.34 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Cummins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.